{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:18Z","timestamp":1783161438461,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019266","name":"Sierra Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019266","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This post hoc analysis investigated the efficacy and safety of momelotinib in the Asian subpopulation of MOMENTUM (NCT04173494).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 2:1 to momelotinib 200\u00a0mg once daily (QD) plus danazol placebo (momelotinib group) or danazol 600\u00a0mg QD plus momelotinib placebo (danazol group) for 24\u00a0weeks (W), after which they could receive open-label momelotinib or danazol. Primary endpoint: W24 total symptom score (TSS) response rate (\u2265\u200950% reduction from baseline). W24 key secondary endpoints: transfusion independence rate; mean TSS change from baseline; splenic response rate; rate of zero transfusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventeen Asian patients with myelofibrosis were included (momelotinib:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911; danazol:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096). TSS response rate at W24 was 36.4% with momelotinib and 0% with danazol. Secondary endpoints favored momelotinib and were consistent with the intention-to-treat population. Grade\u2009\u2265\u20093 treatment-emergent adverse events were reported in 36.4 and 66.7% of the momelotinib and danazol groups, respectively, including one grade\u2009\u2265\u20093 anemia in the momelotinib group. Treatment interruption and\/or dose reduction occurred in 18.2 and 16.7% of the momelotinib and danazol groups, respectively. Two danazol-treated patients discontinued study treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the Asian subpopulation of MOMENTUM, momelotinib improved myelofibrosis-associated symptoms, anemia measures, and spleen response, with generally favorable safety versus danazol.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12185-025-04037-6","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:07:53Z","timestamp":1753139273000},"page":"660-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiat Hoe","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"3","key":"4037_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","volume":"13","author":"K Schepers","year":"2013","unstructured":"Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13(3):285\u201399. https:\/\/doi.org\/10.1016\/j.stem.2013.06.009.","journal-title":"Cell Stem Cell"},{"key":"4037_CR2","doi-asserted-by":"publisher","unstructured":"Iurlo A, Cattaneo D. Treatment of Myelofibrosis: Old and New Strategies. Clin Med Insights Blood Disord. 2017;10:1179545x17695233. https:\/\/doi.org\/10.1177\/1179545x17695233.","DOI":"10.1177\/1179545x17695233"},{"issue":"1","key":"4037_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145\u201362. https:\/\/doi.org\/10.1002\/ajh.26050.","journal-title":"Am J Hematol"},{"issue":"5","key":"4037_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M, Mudireddy M, Lasho TL, Hanson CA, Ketterling RP, Gangat N, et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia. 2018;32(5):1254\u20138. https:\/\/doi.org\/10.1038\/s41375-018-0028-x.","journal-title":"Leukemia"},{"issue":"4","key":"4037_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/jco.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392\u20137. https:\/\/doi.org\/10.1200\/jco.2010.32.2446.","journal-title":"J Clin Oncol"},{"key":"4037_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103862","volume":"180","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Harrison CN, Mesa RA, Kiladjian J-J, Vannucchi AM, Verstovsek S. Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol. 2022;180: 103862.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"4037_CR7","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113(13):2895\u2013901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449.","journal-title":"Blood"},{"issue":"2","key":"4037_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.hoc.2020.11.005","volume":"35","author":"RM Shallis","year":"2021","unstructured":"Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia chromosome-negative classical myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021;35(2):177\u201389. https:\/\/doi.org\/10.1016\/j.hoc.2020.11.005.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"4037_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF, O\u2019Rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581\u20137. https:\/\/doi.org\/10.1002\/ajh.23690.","journal-title":"Am J Hematol"},{"issue":"1","key":"4037_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ejh.12788","volume":"98","author":"C Roaldsnes","year":"2017","unstructured":"Roaldsnes C, Holst R, Frederiksen H, Ghanima W. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017;98(1):85\u201393. https:\/\/doi.org\/10.1111\/ejh.12788.","journal-title":"Eur J Haematol"},{"issue":"3","key":"4037_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","volume":"63","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022;63(3):694\u2013702. https:\/\/doi.org\/10.1080\/10428194.2021.1992756.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"4037_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3346\/jkms.2016.31.10.1579","volume":"31","author":"Y Lim","year":"2016","unstructured":"Lim Y, Lee JO, Bang SM. Incidence, survival and prevalence statistics of classical myeloproliferative Neoplasm in Korea. J Korean Med Sci. 2016;31(10):1579\u201385. https:\/\/doi.org\/10.3346\/jkms.2016.31.10.1579.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"4037_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00277-016-2902-9","volume":"96","author":"JM Byun","year":"2017","unstructured":"Byun JM, Kim YJ, Youk T, Yang JJ, Yoo J, Park TS. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004\u20132013. Ann Hematol. 2017;96(3):373\u201381. https:\/\/doi.org\/10.1007\/s00277-016-2902-9.","journal-title":"Ann Hematol"},{"key":"4037_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102175","volume":"79","author":"HL Htun","year":"2022","unstructured":"Htun HL, Lian W, Wong J, Tan EJ, Foo LL, Ong KH, Lim WY. Classic myeloproliferative neoplasms in Singapore: a population-based study on incidence, trends, and survival from 1968 to 2017. Cancer Epidemiol. 2022;79: 102175. https:\/\/doi.org\/10.1016\/j.canep.2022.102175.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"4037_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","volume":"15","author":"F Seif","year":"2017","unstructured":"Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signaling. 2017;15(1):23. https:\/\/doi.org\/10.1186\/s12964-017-0177-y.","journal-title":"Cell Commun Signaling"},{"issue":"1","key":"4037_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","volume":"14","author":"G Greenfield","year":"2021","unstructured":"Greenfield G, McMullin MF, Mills K. Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol. 2021;14(1):103. https:\/\/doi.org\/10.1186\/s13045-021-01116-z.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"4037_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00277-023-05126-4","volume":"102","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S. How I manage anemia related to myelofibrosis and its treatment regimens. Ann Hematol. 2023;102(4):689\u201398. https:\/\/doi.org\/10.1007\/s00277-023-05126-4.","journal-title":"Ann Hematol"},{"issue":"11","key":"4037_CR18","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2011-11-389866","volume":"119","author":"Z Xu","year":"2012","unstructured":"Xu Z, Gale RP, Zhang Y, Qin T, Chen H, Zhang P, et al. Unique features of primary myelofibrosis in Chinese. Blood. 2012;119(11):2469\u201373. https:\/\/doi.org\/10.1182\/blood-2011-11-389866.","journal-title":"Blood"},{"issue":"13","key":"4037_CR19","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, et al. Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823\u201330. https:\/\/doi.org\/10.1182\/blood-2016-09-740092.","journal-title":"Blood"},{"issue":"10373","key":"4037_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401(10373):269\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(22)02036-0.","journal-title":"Lancet"},{"issue":"34","key":"4037_CR21","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/jco.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus Kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844\u201350. https:\/\/doi.org\/10.1200\/jco.2017.73.4418.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4037_CR22","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/s2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73\u201381. https:\/\/doi.org\/10.1016\/s2352-3026(17)30237-5.","journal-title":"Lancet Haematol"},{"issue":"1","key":"4037_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3324\/haematol.2010.031831","volume":"96","author":"C Elena","year":"2011","unstructured":"Elena C, Passamonti F, Rumi E, Malcovati L, Arcaini L, Boveri E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96(1):167\u201370. https:\/\/doi.org\/10.3324\/haematol.2010.031831.","journal-title":"Haematologica"},{"key":"4037_CR24","doi-asserted-by":"publisher","unstructured":"Mesa R, Palandri F, Verstovsek S, Masarova L, Harrison C, Mazerolle F et al. Pb2184: impact of transfusion burden on health-related quality of life and functioning in patients with myelofibrosis: post hoc analysis of SIMPLIFY-1 and -2. Hemasphere. 2023;7(Suppl):e3210233. https:\/\/doi.org\/10.1097\/01.HS9.0000975488.32102.33.","DOI":"10.1097\/01.HS9.0000975488.32102.33"},{"key":"4037_CR25","doi-asserted-by":"publisher","unstructured":"Feliciano EJG, Ho FDV, Yee K, Paguio JA, Eala MAB, Robredo JPG et al. Cancer disparities in Southeast Asia: intersectionality and a call to action. Lancet Reg Health West Pac. 2023;41. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100971.","DOI":"10.1016\/j.lanwpc.2023.100971"},{"issue":"2","key":"4037_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/0973-6247.83234","volume":"5","author":"N Choudhury","year":"2011","unstructured":"Choudhury N. Blood transfusion in borderless South Asia. Asian J Transfus Sci. 2011;5(2):117\u201320. https:\/\/doi.org\/10.4103\/0973-6247.83234.","journal-title":"Asian J Transfus Sci"},{"issue":"10031","key":"4037_CR27","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(16)30416-0","volume":"387","author":"R Xue","year":"2016","unstructured":"Xue R, Chen Y, Wen J. Blood shortages and donation in China. Lancet. 2016;387(10031):1905. https:\/\/doi.org\/10.1016\/S0140-6736(16)30416-0.","journal-title":"Lancet"},{"key":"4037_CR28","unstructured":"GSK. Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia. 2023. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia\/. November 12, 2023."},{"key":"4037_CR29","unstructured":"European Commission authorises GSK\u2019s Omjjara (momelotinib). https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/european-commission-authorises-gsk-s-omjjara-momelotinib\/. March 26, 2024."},{"key":"4037_CR30","unstructured":"Omjjara licensed for anaemic myelofibrosis patients to treat the symptoms of their disease. https:\/\/www.gov.uk\/government\/news\/omjjara-licensed-for-anaemic-myelofibrosis-patients-to-treat-the-symptoms-of-their-disease#:~:text=The%20Medicines%20and%20Healthcare%20products,blood%20cells%20in%20the%20bloodstream). 26 March, 2024."},{"key":"4037_CR31","unstructured":"GSK. GSK's Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis. 2024. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis\/. July 25, 2024."},{"issue":"3","key":"4037_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/cco.2019.05.01","volume":"8","author":"R Walsh","year":"2019","unstructured":"Walsh R, Goh BC. Population diversity in oncology drug responses and implications to drug development. Chin Clin Oncol. 2019;8(3):24. https:\/\/doi.org\/10.21037\/cco.2019.05.01.","journal-title":"Chin Clin Oncol"},{"key":"4037_CR33","doi-asserted-by":"publisher","unstructured":"Lu Y-S, Yeo W, Yap Y-S, Park YH, Tamura K, Li H, Cheng R. An overview of the treatment efficacy and side effect profile of pharmacological therapies in Asian patients with breast cancer. Targeted Oncol. 2021:701\u201341. https:\/\/doi.org\/10.1007\/s11523-021-00838-x","DOI":"10.1007\/s11523-021-00838-x"},{"issue":"3","key":"4037_CR34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12185-024-03822-z","volume":"120","author":"K Shimoda","year":"2024","unstructured":"Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, et al. Momelotinib versus ruxolitinib in JAK inhibitor-na\u00efve patients with myelofibrosis: an efficacy\/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial. Int J Hematol. 2024;120(3):314\u201324. https:\/\/doi.org\/10.1007\/s12185-024-03822-z.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04037-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:37:19Z","timestamp":1761770239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04037-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4037"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04037-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S-SY\n                      has provided consultancy to Amgen, Janssen, Novartis, and Sanofi, and research funding from Genentech and Pharos iBio.\n                      CCC\n                      reports no conflicts of interest.\n                      S-EL\n                      reports no conflicts of interest.\n                      HC\n                      reports no conflicts of interest.\n                      J-WC\n                      reports no conflicts of interest.\n                      H-AH\n                      has received research support from Abbvie, BMS, Celgene, Kirin and PharmaEssential and honorarium\/travel\/consultancy from Abbvie, Astellas, BeiGene, BMS, Celgene, Chugai, CSL Behring, Daiichi Sankyo, IQVIA, Johnson & Johnson, Kirin, Lotus, Merck Sharp & Dohme, Novartis, Ono, Panco healthcare Co., Pfizer, PharmaEssential, Roche, Synmosa, Takeda, TSH Biopharm, TTY Biopharm Company and Zuellig Pharma.\n                      WSL\n                      reports no conflicts of interest.\n                      S-NL\n                      reports no conflicts of interest.\n                      JHM\n                      reports no conflicts of interest.\n                      KHO\n                      has served on a Janssen Oncology Advisory Board.\n                      YD\n                      is an employee of GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and the International Council for Harmonisation guidelines on Good Clinical Practice. Institutional review boards or independent ethics committees at each site approved the protocol, including the National Health Group Domain Specific Review Board, Seoul National University Hospital Institutional Review Board, Institutional Review Board of Yonsei University Health System, Severance Hospital, Institutional Review Board of Inje University Busan Paik Hospital, Kyungpook National University Hospital Institutional Review Board, Inje University Haeundae Paik Hospital Institutional Review Board, The Catholic University of Korea, Seoul St. Mary\u2019s Hospital Institutional Review Board, Chang Gung Medical Foundation Institutional Review Board, and the Research Ethics Committee of National Taiwan University Hospital. All participants provided written consent. A data monitoring committee reviewed study progress, safety data, and critical efficacy endpoints every six months.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}